Clinical Trial Results: Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial results for poziotinib in non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations have been posted after termination of the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Poziotinib (poziotinib)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: NSCLC | Phase 2 | Status: TERMINATED | Results posted: 2026-06-12